GlassScriptPhysician profile
Pamela Becker
NPI 1255714531
$4,364.52
in general payments reported to CMS, 2019-2025
26 companies · $1,942 in 2025
The $1,942 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $239 · 2022: $644 · 2023: $234 · 2024: $1,306 · 2025: $1,942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,481.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $863.25 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $632.73 | 2021-2025 | |
| Amgen INC. | $503.78 | 2021-2025 | Repatha, Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $458.99 | 2022-2025 | Caplyta |
| Lilly USA, LLC | $456.96 | 2022-2024 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $243.22 | 2022-2025 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $202.54 | 2023-2025 | Airsupra, Breztri |
| Axsome Therapeutics, INC. | $192.02 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $186.74 | 2025 | Rexulti |
| Pfizer INC. | $102.42 | 2024-2025 | |
| Esperion Therapeutics, INC. | $84.58 | 2021 | |
| Mylan Specialty L.P. | $60.28 | 2024 | Yupelri |
| Lundbeck LLC | $52.23 | 2024-2025 | Rexulti |
| Dexcom, INC. | $49.14 | 2024 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $39.58 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $35.69 | 2024 | |
| Exact Sciences Corporation | $34.17 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $30.47 | 2025 | |
| Abbott Laboratories | $22.18 | 2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $20.27 | 2022 | |
| Ardelyx, INC. | $18.28 | 2025 | Ibsrela |
| Antares Pharma, INC. | $16.50 | 2025 | Xyosted |
| Axonics, INC. | $15.23 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.77 | 2025 | Voquezna |
| Ibsa Pharma INC. | $14.31 | 2024 | Licart, Tirosint |
| Takeda Pharmaceuticals U.S.A., INC. | $14.19 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.